Effects of atorvastatin on PDCD4/NF-κB/TNF-α signaling pathway during coronary microembolization of miniature pigs

Experimental and Molecular Pathology

Volumn 99, Issue 3, 2015, Pages 564-569

  Su, Qiang ^a   Li, Lang ^a   Liu, Tao ^a   Wang, Jiangyou ^a   Zhou, You ^a   Liu, Yangchun ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Atorvastatin; Cardiac function; Coronary microembolization; Programmed cell death 4

Indexed keywords

ATORVASTATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; PROGRAMMED CELL DEATH 4 PROTEIN; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY EMBOLISM; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY MICROEMBOLIZATION; DRUG EFFICACY; DRUG MECHANISM; ECHOCARDIOGRAPHY; FEMALE; FLUORESCENCE ANALYSIS; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HEART DILATATION; HEART DISEASE; HEART FUNCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART PROTECTION; HISTOPATHOLOGY; MALE; MINIPIG; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN INDUCTION; SHAM PROCEDURE; SIGNAL TRANSDUCTION; SYSTOLIC DYSFUNCTION; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; DISEASE MODEL; DRUG EFFECTS; EMBOLISM; METABOLISM; PIG; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ATORVASTATIN CALCIUM; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EMBOLISM; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NF-KAPPA B; PERCUTANEOUS CORONARY INTERVENTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SWINE; SWINE, MINIATURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84944031199     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.08.022     Document Type: Article

References (17)

1. Adams S.P., Tsang M., Wright J.M. Lipid lowering efficacy of atorvastatin. Cochrane Database Syst. Rev. 2012, 12:CD008226.
2. Bose D., von Birgelen C., Zhou X.Y., et al. Impact of atherosclerotic plaque composition on coronary microembolization during percutaneous coronary interventions. Basic Res. Cardiol. 2008, 103:587-597.
3. Jaffe R., Charron T., Puley G., et al. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation 2008, 117:3152-3156.
4. Li L., Li D.H., Qu N., et al. The role of ERK1/2 signaling pathway in coronary microembolization-induced rat myocardial inflammation and injury. Cardiology 2010, 117:207-215.
5. Li L., Su Q., Wang Y., et al. Effect of atorvastatin (Lipitor) on myocardial apoptosis and caspase-8 activation following coronary microembolization. Cell Biochem. Biophys. 2011, 61:399-406.
6. Mensah K., Mocanu M.M., Yellon D.M. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten?. J. Am. Coll. Cardiol. 2005, 45:1287-1291.
7. Pasceri V., Patti G., Nusca A., et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (atorvastatin for reduction of MYocardial damage during angioplasty) study. Circulation 2004, 110:674-678.
8. Patti G., Chello M., Pasceri V., et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J. Am. Coll. Cardiol. 2006, 48:1560-1566.
9. Patti G., Pasceri V., Colonna G., et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J. Am. Coll. Cardiol. 2007, 49:1272-1278.
10. Qi Y., Liu J., Ma C., et al. Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease. J. Lipid Res. 2013, 54:3189-3197.
11. Reffelmann T., Kloner R.A. Microvascular alterations after temporary coronary artery occlusion: the no-reflow phenomenon. J. Cardiovasc. Pharmacol. Ther. 2004, 9:163-172.
12. Su Q., Li L., Liu Y.C., et al. Effect of metoprolol on myocardial apoptosis and caspase-9 activation after coronary microembolization in rats. Exp. Clin. Cardiol. 2013, 18:161-165.
13. Su Q., Li L., Zhou Y., et al. Induction of myocardial PDCD4 in coronary microembolization-related cardiac dysfunction: evidence from a large-animal study. Cell. Physiol. Biochem. 2014, 34:533-542.
14. Su Q., Li L., Liu Y., et al. Effect of intensive atorvastatin therapy on periprocedural PDCD4 expression in CD4+ T lymphocytes of patients with unstable angina undergoing percutaneous coronary intervention. Cardiology 2014, 127:169-175.
15. Su Q., Li L., Wang J., et al. Mechanism of programmed cell death factor 4/nuclear factor-κB signaling pathway in porcine coronary micro-embolization-induced cardiac dysfunction. Exp. Biol. Med. 2015, 1535370215573400.
16. Thielmann M., Dorge H., Martin C., et al. Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine. Circ. Res. 2002, 90:807-813.
17. Wang J., Li L., Su Q., et al. The involvement of phosphatase and tensin homolog deleted on chromosome ten (PTEN) in the regulation of inflammation following coronary microembolization. Cell. Physiol. Biochem. 2014, 33:1963-1974.